Ono's antisense therapy is to begin its first pivotal trial.
ApexOnco Front Page
Recent articles
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Median PFS appears to back earlier response rate promise.
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Solstice Oncology acquires porustobart from Harbour Biomed.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
2026’s first big oncology buyout is here.
